Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
Completed · Early Phase 1
Conditions studied: Kidney Cancer, Melanoma (Skin)
In brief
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Interleukin-2 may stimulate the white blood cells, including natural killer cells, to kill melanoma or kidney cancer cells. Giving genistein together with interleukin-2 may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving genistein together with interleukin-2 works in treating patients with metastatic melanoma or kidney cancer.
Key facts
- Study ID
- NCT00276835
- Run by
- Northwestern University
- People needed
- 15
- Starts
- 2005-11-01
- Expected to finish
- 2014-01-01
- Last updated by the study team
- 2015-04-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.